Obstetric and Gynecologic Imaging

What Imaging Is Best for Surveillance of Asymptomatic High-Risk Endometrial Cancer?

·
What Imaging Is Best for Surveillance of Asymptomatic High-Risk Endometrial Cancer?

A 68-year-old woman, two years post-treatment for stage III serous endometrial carcinoma, presents for her routine follow-up. She feels well, has no new complaints, and her pelvic exam is unremarkable. As her gynecologic oncologist, you face a common clinical question: is surveillance imaging warranted to detect an occult recurrence? If so, which study offers the best balance of detection and risk? This scenario—surveillance in an asymptomatic, high-risk patient—is a nuanced decision point where the potential benefits of early detection must be weighed against the risks of radiation exposure and false positives.

This article provides a deep dive into the American College of Radiology (ACR) guidelines for this specific workflow. For this presentation, both Radiography chest and CT of the chest, abdomen, and pelvis are rated as May be appropriate, reflecting the ongoing debate and lack of definitive evidence for one single approach.

Who Fits This Clinical Scenario for High-Risk Endometrial Cancer Surveillance?

This guidance applies specifically to patients who have completed definitive treatment for high-risk endometrial cancer and are currently asymptomatic. The goal of imaging in this context is surveillance for occult recurrence, not diagnosis of a new problem.

Inclusion criteria for this workflow:

  • Completed Primary Treatment: The patient has undergone surgery, and potentially adjuvant chemotherapy and/or radiation therapy.
  • Asymptomatic Status: The patient reports no new or concerning symptoms such as pelvic pain, vaginal bleeding, persistent cough, or unexplained weight loss. The physical examination, including a pelvic exam, is normal.
  • High-Risk Disease Features: This category typically includes patients with high-grade histologies (e.g., serous, clear cell, carcinosarcoma), advanced stage at diagnosis (Stage III or IV), or specific high-risk molecular profiles.

It is critical to distinguish this scenario from similar but distinct clinical situations that require different imaging strategies. This guidance does not apply if:

  • The patient has new symptoms. A patient with symptoms concerning for recurrence (e.g., pelvic pain, new bleeding) should be evaluated under the ACR variant for posttherapy evaluation of clinically suspected recurrence, which prioritizes diagnostic, often cross-sectional, imaging.
  • The patient had low- or intermediate-risk disease. The risk of recurrence in this population is substantially lower, and routine imaging surveillance is generally not recommended. This falls under a separate ACR variant.
  • The patient is undergoing initial staging. Pretreatment evaluation to determine the extent of disease is a different clinical question with its own set of imaging recommendations.

What Diagnoses Are You Working Up in This Scenario?

In the surveillance of an asymptomatic patient, the “differential diagnosis” is less about identifying the cause of a symptom and more about screening for the most likely patterns of disease recurrence. The imaging strategy is designed to detect these subclinical recurrences before they become symptomatic.

Pulmonary Metastases
The lungs are the most common site of distant recurrence for endometrial cancer. Hematogenous spread can lead to the development of pulmonary nodules that are often asymptomatic until they become large or numerous. Chest imaging is primarily aimed at detecting these metastases at an early, potentially treatable, stage.

Abdominopelvic Nodal Recurrence
Recurrence can occur in the pelvic, common iliac, and para-aortic lymph nodes. These nodal metastases are often clinically occult and may only be detectable with cross-sectional imaging. Their presence significantly impacts prognosis and subsequent treatment planning, which may involve targeted radiation or systemic therapy.

Peritoneal Carcinomatosis
Less common but consequential, peritoneal recurrence involves the diffuse seeding of cancer cells throughout the abdominal cavity. In its early stages, it can be asymptomatic and is best detected with contrast-enhanced cross-sectional imaging like CT. This pattern is more frequent in high-grade histologies like serous carcinoma.

Vaginal Cuff or Pelvic Recurrence
While a recurrence at the vaginal cuff is often detected first during a physical exam, imaging can define the extent of the disease and its invasion into adjacent structures. In an asymptomatic patient, a small, deep recurrence might be missed on exam alone, though this is a less common scenario for imaging-only detection.

Why Are Chest Radiography and CT Rated ‘May Be Appropriate’ for Surveillance?

The ACR Appropriateness Criteria rate both chest radiography and comprehensive CT as May be appropriate for this scenario, highlighting the lack of consensus and high-level evidence to mandate one over the other. The choice often depends on institutional protocols, patient-specific risk factors, and a shared decision-making process regarding the tradeoffs between detection sensitivity and cumulative radiation dose.

Rationale for Radiography chest (Rating: May be appropriate)
A chest radiograph directly targets the most common site of distant recurrence: the lungs. Its primary advantage is its extremely low radiation dose (☢ <0.1 mSv). For patients undergoing years of follow-up, minimizing cumulative radiation exposure is a significant consideration. It serves as a reasonable, low-impact screening test. However, its sensitivity for small pulmonary nodules is lower than that of CT, and it provides no information about potential abdominopelvic recurrence.

Rationale for CT chest abdomen pelvis with IV contrast (Rating: May be appropriate)
This study provides a comprehensive, “one-stop” survey for recurrence in the chest, lymph nodes, peritoneum, and solid abdominal organs. Its high spatial resolution makes it more sensitive than radiography for detecting small pulmonary nodules and is the modality of choice for identifying nodal and peritoneal disease. The use of IV contrast is crucial for delineating lymph nodes and evaluating visceral organs. The major drawback is the substantial radiation dose (☢☢☢☢ 10-30 mSv), which can become a concern with repeated annual scans.

Why Other Studies Are Rated Lower for This Scenario

  • MRI pelvis without and with IV contrast (Rating: Usually not appropriate): While MRI is excellent for problem-solving a suspected pelvic abnormality found on exam or another imaging study, its role as a primary screening tool in an asymptomatic patient is limited. It is more costly, less available, and does not evaluate the chest or upper abdomen, common sites of distant recurrence.
  • US pelvis transvaginal (Rating: Usually not appropriate): Ultrasound is highly effective for evaluating the uterus and adnexa but is not a suitable tool for surveillance after hysterectomy. It cannot assess for nodal disease, peritoneal implants, or distant metastases, making it inadequate for comprehensive recurrence screening.

What’s Next After Radiography chest? Downstream Workflow

The results of surveillance imaging will guide the subsequent clinical pathway. The goal is to efficiently confirm or exclude recurrence while minimizing unnecessary interventions for benign or indeterminate findings.

If the surveillance study is negative:
Whether a chest radiograph or a full CT, a negative result is reassuring. The patient should continue with their established follow-up schedule, which typically includes regular clinical visits and physical exams. No further immediate imaging is required.

If the chest radiograph is positive or equivocal:
A new or growing pulmonary nodule on a chest radiograph is a key trigger for further investigation. The standard next step is a diagnostic CT of the chest (with or without contrast) to better characterize the finding’s size, morphology, and number. Depending on the CT findings and level of suspicion, this may lead to PET/CT for staging or a biopsy for definitive diagnosis.

If the CT chest, abdomen, and pelvis is positive:
A finding on CT suspicious for recurrence (e.g., an enlarged lymph node, a new liver lesion, or omental caking) fundamentally changes the patient’s status from “surveillance” to “suspected recurrence.” The next step is nearly always to obtain a tissue diagnosis via image-guided biopsy. A PET/CT scan may also be performed to determine the full extent of metabolic activity and guide the most appropriate biopsy site.

If the study is indeterminate:
Indeterminate findings, such as a sub-centimeter pulmonary nodule or a borderline-sized lymph node, are a common challenge. Management may involve short-interval follow-up imaging (e.g., a repeat CT in 3-6 months) to assess for stability or growth, which helps differentiate benign processes from early recurrence.

Pitfalls to Avoid (and When to Get Help)

Navigating surveillance for high-risk endometrial cancer requires careful attention to avoid common missteps that can lead to patient harm or diagnostic delay.

  • Pitfall 1: Applying surveillance guidelines to a symptomatic patient. If a patient reports new vaginal bleeding, pelvic pain, or constitutional symptoms, they are no longer “asymptomatic.” This presentation requires a diagnostic workup, not a surveillance scan, and falls under the ACR variant for suspected recurrence.
  • Pitfall 2: Overlooking cumulative radiation dose. Ordering annual high-dose CT scans for many years without revisiting the risk/benefit profile can lead to significant cumulative radiation exposure. Consider alternating with chest radiography or spacing out CT scans after the initial high-risk period (2-3 years post-treatment).
  • Pitfall 3: The “incidentaloma” chase. Comprehensive CT scans frequently uncover incidental findings unrelated to cancer recurrence (e.g., adrenal adenomas, renal cysts). It is crucial to have a systematic approach to these findings to avoid extensive, costly, and anxiety-provoking workups for benign lesions.

If a patient develops clear symptoms of recurrence or if imaging reveals a definitive lesion, escalation to a multidisciplinary tumor board including gynecologic oncology, radiology, and radiation oncology is the appropriate next step to formulate a treatment plan.

Related ACR Topics and Tools

This article covers one specific variant within the broader topic of endometrial cancer imaging. For a comprehensive overview of all related clinical scenarios, from initial staging to the workup of suspected recurrence, please consult the parent topic article. The following GigHz tools can also support your clinical workflow.

Frequently Asked Questions

What defines ‘high-risk’ endometrial cancer for surveillance purposes?

High-risk features typically include advanced FIGO stage (III-IV), high-grade histology (e.g., serous, clear cell, carcinosarcoma), or certain molecular subtypes with a higher propensity for recurrence. These criteria are defined by organizations like the Society of Gynecologic Oncology (SGO) and are used to stratify patients who may benefit from more intensive follow-up.

Is PET/CT ever appropriate for routine surveillance in asymptomatic patients?

No, according to the ACR Appropriateness Criteria, PET/CT is ‘Usually not appropriate’ for routine surveillance in asymptomatic patients. Its use is reserved for specific indications, such as evaluating a suspected recurrence found on another imaging study or for restaging confirmed recurrent disease before starting new treatment.

How often should surveillance imaging be performed?

The optimal frequency is not definitively established and varies by institutional protocol and national guidelines (e.g., NCCN). A common approach is annual imaging for the first 2-5 years after treatment, when the risk of recurrence is highest. This article focuses on which study to order, not the specific timing interval.

Why isn’t routine imaging recommended for low- or intermediate-risk endometrial cancer survivors?

For patients with low- or intermediate-risk disease, the absolute risk of recurrence is very low. In this population, the potential harms of routine imaging—including radiation exposure, cost, false positives, and patient anxiety—are considered to outweigh the small chance of detecting an asymptomatic recurrence. Most recurrences in this group are detected due to the onset of new symptoms.

If a physical exam is abnormal, does this imaging guidance still apply?

No. An abnormal physical exam finding, such as a palpable nodule at the vaginal cuff, means the patient is no longer asymptomatic. This shifts the clinical scenario to ‘Posttherapy evaluation of clinically suspected recurrence,’ which calls for a diagnostic imaging workup (often with pelvic MRI or CT) rather than a surveillance study.

Reviewed by Pouyan Golshani, MD, Interventional Radiologist — May 29, 2026